{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:13:57Z","timestamp":1783199637779,"version":"3.54.6"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jaci.2026.02.007","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:50:09Z","timestamp":1771433409000},"page":"1433-1441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SIGLEC-1 expression on monocytes as a diagnostic biomarker in pediatric type I interferon-mediated diseases"],"prefix":"10.1016","volume":"157","author":[{"given":"Valentina","family":"Matteo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Zeric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Loricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Caiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Martella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Guarracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Agrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Federici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nicita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bracaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Messia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Insalaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1152-9041","authenticated-orcid":false,"given":"Giusi","family":"Prencipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.02.007_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I interferonopathies: a novel set of inborn errors of immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaci.2026.02.007_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11926-020-00909-4","article-title":"Type I interferonopathies: from a novel concept to targeted therapeutics","volume":"22","author":"Melki","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jaci.2026.02.007_bib3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/keab673","article-title":"Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)","volume":"61","author":"Verweyen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2026.02.007_bib4","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1056\/NEJMc1810983","article-title":"Reverse-transcriptase inhibitors in the Aicardi\u2013Gouti\u00e8res syndrome","volume":"379","author":"Rice","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.02.007_bib5","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1177\/09612033241261746","article-title":"Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: a qualitative study in Denmark","volume":"33","author":"Troldborg","year":"2024","journal-title":"Lupus"},{"key":"10.1016\/j.jaci.2026.02.007_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/1744666X.2023.2268284","article-title":"Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus","volume":"20","author":"Gensous","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2026.02.007_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10875-024-01826-2","article-title":"Normalized interferon signatures and clinical improvements by IFNAR1 blocking antibody (anifrolumab) in patients with type I interferonopathies","volume":"45","author":"Kretzschmar","year":"2024","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2026.02.007_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10875-024-01851-1","article-title":"Anifrolumab in monogenic lupus caused by TREX1 mutation","volume":"45","author":"Moran-Alvarez","year":"2024","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2026.02.007_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41584-024-01184-8","article-title":"Emerging concepts and treatments in autoinflammatory interferonopathies and monogenic systemic lupus erythematosus","volume":"21","author":"Goldbach-Mansky","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2026.02.007_bib10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.31138\/mjr.270324.tis","article-title":"Type I interferons in systemic autoimmune rheumatic diseases: pathogenesis, clinical features and treatment options","volume":"35","author":"Drougkas","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"10.1016\/j.jaci.2026.02.007_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of type I interferon signaling in pediatric inflammatory disease","volume":"37","author":"Rice","year":"2017","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2026.02.007_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002864","article-title":"Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider","volume":"9","author":"Rodr\u00edguez-Carrio","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2026.02.007_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001934","article-title":"SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies","volume":"8","author":"Graf","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2026.02.007_bib14","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response","volume":"61","author":"Lerkvaleekul","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2026.02.007_bib15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3390\/ph15101198","article-title":"SIGLEC-1 in systemic sclerosis: a useful biomarker for differential diagnosis","volume":"15","author":"H\u00f6ppner","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jaci.2026.02.007_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sj\u00f6gren\u2019s syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2026.02.007_bib17","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1177\/0961203320965699","article-title":"SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus","volume":"29","author":"von Stuckrad","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.jaci.2026.02.007_bib18","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1093\/rheumatology\/keab875","article-title":"Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus","volume":"61","author":"Zorn-Pauly","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2026.02.007_bib19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13075-018-1649-1","article-title":"The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus","volume":"20","author":"Oliveira","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2026.02.007_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109329","article-title":"CD169 expression on monocytes as a marker for assessing type I interferon status in pediatric inflammatory diseases","volume":"250","author":"Sakumura","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2026.02.007_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1520","article-title":"Siglec-1, an easy and contributory inflammation marker in rheumatology","volume":"13","author":"Boz","year":"2024","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.jaci.2026.02.007_bib22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","article-title":"Assessment of interferon-related biomarkers in Aicardi-Gouti\u00e8res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study","volume":"12","author":"Rice","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaci.2026.02.007_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajmg.a.36887","article-title":"Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1","volume":"167A","author":"Crow","year":"2015","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jaci.2026.02.007_bib24","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI129301","article-title":"Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases","volume":"130","author":"de Jesus","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.02.007_bib25","article-title":"Profiling type I and II interferon responses reveals distinct subgroups of pediatric patients with autoinflammatory disorders","volume":"4","author":"Nombel","year":"2025","journal-title":"J Allergy Clin Immunol Glob"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:57:47Z","timestamp":1780567067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926000886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0091674926000886"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.02.007","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SIGLEC-1 expression on monocytes as a diagnostic biomarker in pediatric type I interferon-mediated diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}